Pixium Vision
Pixium Vision [ALPIX] is developing retinal implant systems for patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. The Company intends to harness the rapid advances being made in neural processing, micro-electronics and computing to develop retinal implant systems that for blind people could ultimately provide vision approaching that of a normal healthy eye.
Pixium’s first device, IRIS1 (Intelligent Retinal Implantable System), uses an epi-retinal implant (on the retinal surface) and is currently in clinical trials with the goal of obtaining CE Mark. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development. In addition, Pixium is developing a sub-retinal implant system (IRIS3), based on further technological breakthroughs, which has the potential to improve vision significantly compared to IRIS1 and IRIS2.
Pixium was created in Paris, France in November 2011 as a spin-out of the Vision Institute and Université Pierre et Marie Curie.
Sector
Medical Devices
Strategy
Capital
Status
Live
Website
www.pixium-vision.com
Related News
Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024
Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera
Pixium Vision receives French regulatory authority (ANSM) approval to initiate European PRIMAvera pivotal study of Prima System
Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study
Pixium Vision announces positive follow-up data from Prima System study in dry AMD
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.